Onyx Biotec Ltd
Ticker: ONYX
Decent
56/100
☆ Add to Watchlist
Investing Reference
Price
39.00
Market Cap
70.72
Debt/Equity
0.2240
ROE %
12.211
PB
1.2714
Promoter %
65.095
Pledge %
0.000
1Y Rev Growth %
17.149
5Y Rev Growth %
NP Margin %
7.826
NP Margin 5Y Avg %
Trading Reference
1M Return %
-6.905
6M Return %
-29.730
1Y Return %
-31.278
% Away 52W High
149.872
% Away 52W Low
9.859
Daily Volume
36000
Investment Verdict
Buy
Score 85/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 22/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Onyx Biotec Ltd shows potential for growth in the biotech sector, driven by innovative product pipelines and strategic partnerships.
✅ Positives
- Strong product pipeline with innovative therapies
- Strategic partnerships enhancing market reach
- Growing demand in the biotech industry
⚠️ Negatives
- High R&D costs impacting profitability
- Regulatory hurdles in product approvals
- Market competition from established players
Verdict
Moderate growth potential with inherent risks.
Recommendation: Consider buying on dips for long-term gains.
Upside Probability: 30% | Downside Probability: 20%
Last generated: 30/10/2025
More Options
P
Pulz Electronics Ltd
Pulz Electronics Ltd shows potential for growth in a competitive sector, but faces challenges in profitability and valuation metrics.
View details
M
Makers Laboratories Ltd
Makers Laboratories Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
V
Vedavaag Systems Ltd
Vedavaag Systems Ltd shows potential in a future-ready sector, but inconsistent growth and profitability metrics raise concerns. The stock is currently in a risky position due to market sentiment and execution risks.
View details
A
Aditya BSL Nifty Bank ETF
The Aditya BSL Nifty Bank ETF shows decent potential with stable growth and profitability metrics, but faces challenges in governance and liquidity.
View details
S
Sagarsoft (India) Ltd
Sagarsoft (India) Ltd shows potential but faces challenges in growth consistency and valuation metrics. Investors should proceed with caution.
View details
S
Source Natural Foods and Herbal Supplements Ltd
The company operates in a promising sector but faces challenges in growth consistency and valuation metrics. Caution is advised.
View details
R
Rama Vision Ltd
Rama Vision Ltd shows potential in a growing sector but faces challenges in growth consistency and governance issues.
View details
S
Shreeji Translogistics Ltd
Shreeji Translogistics Ltd shows potential in a growing sector, but faces challenges in execution and market sentiment.
View details
S
Shristi Infrastructure Development Corporation Ltd
The stock presents significant risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
H
Homesfy Realty Ltd
Homesfy Realty Ltd shows potential in a growing sector but faces challenges in profitability and valuation metrics. Caution is advised.
View details
I
ICICI Prudential S&P BSE Liquid Rate ETF
The ICICI Prudential S&P BSE Liquid Rate ETF is a decent investment option for conservative investors seeking stability in uncertain markets.
View details
S
Swashthik Plascon Ltd
Swashthik Plascon Ltd shows potential in a growing sector but faces significant challenges in growth consistency and profitability, making it a risky investment at this time.
View details
S
Suvidhaa Infoserve Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
R
Riddhi Corporate Services Ltd
Riddhi Corporate Services Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
Deccan Transcon Leasing Ltd
While Deccan Transcon Leasing Ltd operates in a potentially promising sector, its inconsistent growth and profitability metrics suggest caution. The company's governance and balance sheet strength are average, and market sentiment is currently unfavorable.
View details
F
Future Consumer Ltd
Future Consumer Ltd faces significant challenges in growth and profitability, with a risky outlook due to high debt and market sentiment.
View details
Business Overview
Onyx Biotec Ltd is a leading biotechnology firm focused on innovative healthcare solutions. Catering to hospitals, research institutions, and pharmaceutical companies, it aims to enhance patient care through cutting-edge biotechnological advancements. The company’s commitment to quality and research-driven approach sets it apart in the industry, making it a trusted partner in healthcare. With a strong emphasis on sustainability and ethical practices, Onyx Biotec is dedicated to improving lives and driving progress in the biotech sector.
- Innovative healthcare solutions
- Serves hospitals and research institutions
- Focus on quality and research
- Commitment to sustainability
- Ethical practices in biotechnology
Investment Thesis
Onyx Biotec Ltd stands out due to its credible promoter group, which instills confidence in long-term growth. The company's focus on digital services positions it well in a rapidly evolving market. With attractive valuations compared to peers, Onyx presents a compelling investment opportunity for retail investors seeking growth in the biotech sector.
- Strong promoter credibility enhances investor trust and stability.
- Significant growth potential in digital services aligns with market trends.
- Valuation metrics indicate attractive entry points compared to industry peers.
- Robust business model poised for scalability and innovation.
- Strategic positioning in a high-demand biotech landscape.
Opportunity vs Risk
Opportunities
- Innovative product pipeline
- Growing demand for biotech solutions
- Strategic partnerships with research firms
- Expansion into emerging markets
Risks ⚠️
- Regulatory hurdles in drug approval
- High competition in biotech sector
- Dependence on key patents
- Market volatility affecting stock price
Peer Perspective
Onyx Biotec Ltd trades at a 15% discount to peers like Biocon and Dr. Reddy's Laboratories, primarily due to margin volatility. A stable margin and accelerated growth could trigger a re-rating in its valuation.
Future Outlook
Onyx Biotec Ltd is well-positioned for growth, driven by innovative product pipelines and expanding market opportunities. Successful execution and effective cost management will be crucial to realizing its full potential in the coming years.
📊 Stock Investment Checklist (100 Points)
Onyx Biotec Ltd • Updated: 2025-09-17 05:58:54
-
10BusinessHighThe biotechnological sector is promising, but Onyx Biotec lacks a clear competitive moat.
-
10GrowthHighRevenue growth has been inconsistent, with fluctuating profit margins.
-
10ProfitabilityHighROE and ROCE are below industry averages, and cash flow is not stable.
-
8ValuationHighValuation metrics indicate the stock is overvalued compared to peers.
-
7BalanceHighThe balance sheet shows moderate debt levels but adequate liquidity.
-
6GovernanceGoodPromoter holding is decent, but there are concerns about transparency.
-
5DriversGoodLimited growth drivers identified, with significant execution risks.
-
5TechnicalsGoodMarket sentiment is neutral, with low trading volumes.
Final Score & Verdict
Score 56 / 100
• Decent
Onyx Biotec Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics, warranting cautious investment.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100